Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | See Remarks | January 23, 2026 | January 26, 2026 |
| Cidara Therapeutics, Inc.CDTX · Entity 69639 | General Counsel & Secretary | January 05, 2021 | April 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date January 23, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-01-22 | Direct | 220,000 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 220,000 · Balance 220,000 F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.
Cidara Therapeutics, Inc.
Report date January 05, 2021 · Filed April 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,764 |
Ending reported balance
After 2021-04-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-01-05 · Sale · Disposed 824 · Balance 6,141 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 1/1/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Row 2 · 2021-03-31 · Grant · Acquired 2,800 · Balance 8,941 F2: The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21. Row 3 · 2021-04-01 · Sale · Disposed 1,177 · Balance 7,764 F3: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs on 03/31/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 1/1/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2: The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21.
F3: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs on 03/31/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 26, 2026 07:00 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001193125-26-021658 · ownership.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. Read SEC document |
| January 22, 2025 Filed Jan 23, 2025 16:05 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 90,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0000950170-25-008317 · ownership.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on February 1, 2025. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 16,234 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 14 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,234 Underlying: Common Stock · 16,234 shares Expires 2034-03-26 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 26,090 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 13 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,090 Underlying: Common Stock · 26,090 shares Expires 2034-02-14 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 35,897 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 12 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,897 Underlying: Common Stock · 35,897 shares Expires 2033-12-12 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 42,051 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 11 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,051 Underlying: Common Stock · 42,051 shares Expires 2033-06-12 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 10,200 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 10 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,200 Underlying: Common Stock · 10,200 shares Expires 2032-12-12 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 29,148 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 9 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,148 Underlying: Common Stock · 29,148 shares Expires 2031-12-05 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 32,051 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 8 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,051 Underlying: Common Stock · 32,051 shares Expires 2031-09-14 F9 · derivative.exercise_price: The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "premium end date" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a "qualifying termination" (as defined below). The "premium end date" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A "qualifying termination" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability. F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on August 30, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 16,234 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 7 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,234 shares Expires 2034-03-26 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F8 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 26,090 | Not disclosed Strike: $8.19 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 6 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,090 shares Expires 2034-02-14 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F7 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 35,897 | Not disclosed Strike: $4.49 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 5 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,897 shares Expires 2033-12-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F6 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2024. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 42,051 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 4 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,051 shares Expires 2033-06-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F5 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 10,200 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 3 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,200 shares Expires 2032-12-12 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F4 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 13, 2023. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 29,148 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 2 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,148 shares Expires 2031-12-05 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F3 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 19:11 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | Disposition to issuerStock Option · Derivative | 32,051 | Not disclosed Strike: $4.10 | Not disclosed |
DisclosureSEC source: 0000950170-24-099307 · ownership.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,051 shares Expires 2031-09-14 F2 · price: On August 19, 2024, the Issuer repriced the option. Except as further described in footnote 9, all other terms of the option remain unchanged. F1 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on August 30, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 16:30 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 16,234 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000950170-24-038699 · ownership.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,234 Underlying: Common Stock · 16,234 shares Expires 2034-03-26 F1 · derivative.exercise_date: The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 17:35 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 1,177 | $2.66 | $3,130.82 |
DisclosureSEC source: 0001610618-21-000030 · wf-form4_161765846617206.xml · nonDerivative · entry 3 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,764 F3 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs on 03/31/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 31, 2021 Filed Apr 5, 2021 17:35 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001610618-21-000030 · wf-form4_161765846617206.xml · nonDerivative · entry 2 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,941 F2 · shares: The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21. Read SEC document |
| March 17, 2021 Filed Mar 19, 2021 21:00 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001610618-21-000018 · wf-form4_161620203129692.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2031-03-16 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021. Read SEC document |
| January 05, 2021 Filed Apr 5, 2021 17:35 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 824 | $2.06 | $1,697.44 |
DisclosureSEC source: 0001610618-21-000030 · wf-form4_161765846617206.xml · nonDerivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,141 F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 1/1/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 19, 2020 Filed Mar 23, 2020 19:21 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001209191-20-020753 · doc4.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2030-03-18 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:28 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 834 | $3.86 | $3,219.24 |
DisclosureSEC source: 0001209191-20-002038 · doc4.xml · nonDerivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,965 F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 17:07 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | SaleCommon Stock | 1,001 | $1.86 | $1,861.86 |
DisclosureSEC source: 0001209191-19-051327 · doc4.xml · nonDerivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,799 F1 · shares: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 9/12/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 17:28 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Exercise / conversionRestricted Stock Unit · Derivative | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049684 · doc4.xml · derivative · entry 2 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 Underlying: Common Stock · 2,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · shares: This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19. F3 · derivative.exercise_date: A portion of the shares vest upon the achievement of various clinical and corporate milestones. F3 · derivative.expiration_date: A portion of the shares vest upon the achievement of various clinical and corporate milestones. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 17:28 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 2,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-049684 · doc4.xml · nonDerivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 F1 · shares: This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19. Read SEC document |
| March 21, 2019 Filed Mar 22, 2019 16:47 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-19-021008 · doc4.xml · derivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-03-20 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 21, 2019. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 19:03 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Exercise / conversionRestricted Stock Unit · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006609 · doc4.xml · derivative · entry 2 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2022-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares shall vest upon the achievement of various clinical and corporate milestones. Read SEC document |
| January 31, 2019 Filed Feb 1, 2019 19:03 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-006609 · doc4.xml · nonDerivative · entry 1 Oien Jessica · CIK 0001760712 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: 1/3rd of the total number of shares subject to the restricted stock unit shall vest on each January 1 of 2020, 2021 and 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.